Under the terms of this agreement, Tabuk Pharmaceuticals will hold the marketing authorisation and will be responsible for registering, importing, and commercialising VOLT01 in the MEA region
Tabuk Pharmaceutical Manufacturing Company has signed an exclusive licence and distribution agreement with US’ Levolta Pharmaceuticals to commercialise an investigational osteoarthritis (OA) therapy in Middle East and Africa.